Menopausal hormone therapy prior to the diagnosis of ovarian cancer is associated with improved survival.

Aged Estrogen Replacement Therapy / statistics & numerical data Female Hormone Replacement Therapy / statistics & numerical data Humans Middle Aged Neoplasm Staging Neoplasm, Residual / pathology Ovarian Neoplasms / mortality Postmenopause Progestins / administration & dosage Progression-Free Survival Proportional Hazards Models Survival Rate

Journal

Gynecologic oncology
ISSN: 1095-6859
Titre abrégé: Gynecol Oncol
Pays: United States
ID NLM: 0365304

Informations de publication

Date de publication:
09 2020
Historique:
received: 02 04 2020
accepted: 07 06 2020
pubmed: 10 7 2020
medline: 16 4 2021
entrez: 10 7 2020
Statut: ppublish

Résumé

Prior studies of menopausal hormone therapy (MHT) and ovarian cancer survival have been limited by lack of hormone regimen detail and insufficient sample sizes. To address these limitations, a comprehensive analysis of 6419 post-menopausal women with pathologically confirmed ovarian carcinoma was conducted to examine the association between MHT use prior to diagnosis and survival. Data from 15 studies in the Ovarian Cancer Association Consortium were included. MHT use was examined by type (estrogen-only (ET) or estrogen+progestin (EPT)), duration, and recency of use relative to diagnosis. Cox proportional hazards models were used to estimate the association between hormone therapy use and survival. Logistic regression and mediation analysis was used to explore the relationship between MHT use and residual disease following debulking surgery. Use of ET or EPT for at least five years prior to diagnosis was associated with better ovarian cancer survival (hazard ratio, 0.80; 95% CI, 0.74 to 0.87). Among women with advanced stage, high-grade serous carcinoma, those who used MHT were less likely to have any macroscopic residual disease at the time of primary debulking surgery (p for trend <0.01 for duration of MHT use). Residual disease mediated some (17%) of the relationship between MHT and survival. Pre-diagnosis MHT use for 5+ years was a favorable prognostic factor for women with ovarian cancer. This large study is consistent with prior smaller studies, and further work is needed to understand the underlying mechanism.

Identifiants

DOI: 10.1016/j.ygyno.2020.06.481 PMID: 32641237 PMC: PMC7487048
pubmed: 32641237
pii: S0090-8258(20)32296-4
doi: 10.1016/j.ygyno.2020.06.481
pmc: PMC7487048
mid: NIHMS1609486
pii:
doi:

Substances chimiques

Progestins 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, N.I.H., Intramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

702-709

Subventions

Organisme : NCI NIH HHS
ID : R01 CA087538
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA063678
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA105009
Pays : United States
Organisme : NCI NIH HHS
ID : K07 CA080668
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NIGMS NIH HHS
ID : T32 GM007863
Pays : United States
Organisme : NCI NIH HHS
ID : R03 CA115195
Pays : United States
Organisme : NCI NIH HHS
ID : K07 CA095666
Pays : United States
Organisme : NCI NIH HHS
ID : N01 PC067010
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA159981
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA072720
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA095023
Pays : United States
Organisme : NCI NIH HHS
ID : R03 CA113148
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA058598
Pays : United States
Organisme : NCI NIH HHS
ID : K22 CA138563
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA058860
Pays : United States
Organisme : NCRR NIH HHS
ID : M01 RR000056
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA080742
Pays : United States
Organisme : Medical Research Council
ID : MC_UU_12023/20
Pays : United Kingdom
Organisme : NHGRI NIH HHS
ID : T32 HG000040
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA074850
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA014089
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA083918
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA054419
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA122443
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA015083
Pays : United States
Organisme : NCI NIH HHS
ID : P01 CA017054
Pays : United States
Organisme : NCI NIH HHS
ID : N01 CN025403
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA112523
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA136393
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA126841
Pays : United States
Organisme : Cancer Research UK
ID : 10119
Pays : United Kingdom

Informations de copyright

Copyright © 2020 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest Usha Menon has stocks in Abcodia awarded to her by University College London.

Références

JAMA. 2013 Oct 2;310(13):1353-68
pubmed: 24084921
J Clin Oncol. 2006 Aug 1;24(22):3576-82
pubmed: 16877724
JAMA. 2002 Jul 17;288(3):321-33
pubmed: 12117397
Int J Gynaecol Obstet. 2018 Oct;143 Suppl 2:2-3
pubmed: 30306587
Br J Cancer. 2015 Dec 1;113(11):1622-31
pubmed: 26554655
Adv Clin Chem. 2009;47:59-93
pubmed: 19634777
Int J Cancer. 2006 Dec 15;119(12):2907-15
pubmed: 16998830
Cancer Sci. 2008 Aug;99(8):1501-6
pubmed: 18754859
Lancet. 2015 May 9;385(9980):1835-42
pubmed: 25684585
Cancer Causes Control. 2008 Aug;19(6):605-13
pubmed: 18264784
BMJ. 1991 Feb 2;302(6771):259-62
pubmed: 1998789
Cancer. 1999 Sep 15;86(6):1013-8
pubmed: 10491528
Joint Bone Spine. 2013 Jul;80(4):368-73
pubmed: 23352515
Menopause. 2001 Jan-Feb;8(1):70-5
pubmed: 11201519
Int J Gynecol Cancer. 2008 May-Jun;18(3):407-13
pubmed: 17645507
J Natl Cancer Inst. 2014 Apr 03;106(5):
pubmed: 24700803
Lancet. 2007 May 19;369(9574):1703-10
pubmed: 17512855
Menopause. 2008 Mar-Apr;15(2):282-9
pubmed: 17998884
Psychol Methods. 2010 Dec;15(4):309-34
pubmed: 20954780
Menopause. 2020 Feb;27(2):243-248
pubmed: 31738735
Eur J Cancer Prev. 2013 Jan;22(1):52-8
pubmed: 22694828
Gynecol Oncol Rep. 2015 May 08;13:13-7
pubmed: 26425711
Gynecol Oncol. 2015 Dec;139(3):394-400
pubmed: 26348314
Eur J Gynaecol Oncol. 2000;21(2):192-6
pubmed: 10843485
Obstet Gynecol. 2016 May;127(5):828-36
pubmed: 27054934
Br J Cancer. 2016 Nov 22;115(11):1391-1399
pubmed: 27701384
Cancer. 2018 Jul 1;124(13):2785-2800
pubmed: 29786848
Arch Intern Med. 1999 May 24;159(10):1061-6
pubmed: 10335682
Endocr Rev. 2007 Aug;28(5):521-74
pubmed: 17640948
Climacteric. 2013 Dec;16(6):673-81
pubmed: 23710587
Obstet Gynecol. 2016 May;127(5):837-47
pubmed: 27054933
Am J Cardiol. 2003 Jan 15;91(2):252-4
pubmed: 12521647
J Womens Health (Larchmt). 2006 Jan-Feb;15(1):35-44
pubmed: 16417416
J Clin Oncol. 2015 Dec 10;33(35):4138-44
pubmed: 26417001
N Engl J Med. 2016 Mar 31;374(13):1221-31
pubmed: 27028912
J Obstet Gynaecol Res. 2012 Jan;38(1):40-7
pubmed: 22070411
Br J Cancer. 2017 Mar 28;116(7):964-971
pubmed: 28208158
Oncol Lett. 2012 Jan;3(1):244-249
pubmed: 22740889

Auteurs

Katharine K Brieger (KK)

Department of Epidemiology, University of Michigan School of Public Health, Ann Arbor, MI, USA.

Siri Peterson (S)

Department of Epidemiology, University of Michigan School of Public Health, Ann Arbor, MI, USA.

Alice W Lee (AW)

Department of Public Health, California State University Fullerton, Fullerton, CA, USA.

Bhramar Mukherjee (B)

Department of Epidemiology, University of Michigan School of Public Health, Ann Arbor, MI, USA; Department of Biostatistics, University of Michigan School of Public Health, Ann Arbor, MI, USA.

Kelly M Bakulski (KM)

Department of Epidemiology, University of Michigan School of Public Health, Ann Arbor, MI, USA.

Aliya Alimujiang (A)

Department of Epidemiology, University of Michigan School of Public Health, Ann Arbor, MI, USA.

Hoda Anton-Culver (H)

Department of Medicine, University of California Irvine, Irvine, CA, USA.

Michael S Anglesio (MS)

Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, Canada.

Elisa V Bandera (EV)

Cancer Prevention and Control Program, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.

Andrew Berchuck (A)

Division of Gynecologic Oncology, Duke University School of Medicine, Durham, NC, USA.

David D L Bowtell (DDL)

Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Victoria, Australia.

Georgia Chenevix-Trench (G)

Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.

Kathleen R Cho (KR)

Department of Pathology, University of Michigan Medical School, Ann Arbor, MI, USA.

Daniel W Cramer (DW)

Department of Epidemiology, Harvard TH Chan School of Public Health, Boston, MA, USA; Obstetrics and Gynecology Epidemiology Center, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.

Anna DeFazio (A)

Centre for Cancer Research, The Westmead Institute for Medical Research, The University of Sydney, Australia; Department of Gynaecological Oncology, Westmead Hospital, Westmead, New South Wales, Australia.

Jennifer A Doherty (JA)

Huntsman Cancer Institute, Department of Population Health Sciences, University of Utah, Salt Lake City, UT, USA.

Renée T Fortner (RT)

Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.

Dale W Garsed (DW)

Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Victoria, Australia.

Simon A Gayther (SA)

Cedars Sinai Medical Center, Los Angeles, CA, USA.

Aleksandra Gentry-Maharaj (A)

MRC Clinical Trials Unit at UCL, Institute of Clinical Trials & Methodology, University College London, London, UK.

Ellen L Goode (EL)

Department of Health Science Research, Division of Epidemiology, Mayo Clinic, Rochester, MN, USA.

Marc T Goodman (MT)

Samuel Oschin Comprehensive Cancer Institute, Cancer Prevention and Genetics Program, Cedars-Sinai Medical Center, Los Angeles, CA, USA; Community and Population Health Research Institute, Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA, USA.

Holly R Harris (HR)

Program in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA; Department of Epidemiology, University of Washington, Seattle, WA, USA.

Estrid Høgdall (E)

Department of Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark; Molecular Unit, Department of Pathology, Herlev Hospital, University of Copenhagen, Copenhagen, Denmark.

David G Huntsman (DG)

Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, Canada; Department of Molecular Oncology, BC Cancer Research Centre, Vancouver, Canada.

Hui Shen (H)

Van Andel Research Institute (VARI), Grand Rapids, MI, USA.

Allan Jensen (A)

Department of Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark.

Sharon E Johnatty (SE)

Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.

Susan J Jordan (SJ)

University of Queensland, School of Public Health, Brisbane, Australia; Department of Population Health, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.

Susanne K Kjaer (SK)

Department of Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark; Department of Gynaecology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.

Jolanta Kupryjanczyk (J)

Department of Pathology and Laboratory Diagnostics, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland.

Diether Lambrechts (D)

Vesalius Research Center, VIB, Leuven, Belgium; Laboratory for Translational Genetics, Department of Oncology, University of Leuven, Leuven, Belgium.

Karen McLean (K)

Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Michigan Medical School, Ann Arbor, MI, USA.

Usha Menon (U)

MRC Clinical Trials Unit at UCL, Institute of Clinical Trials & Methodology, University College London, London, UK.

Francesmary Modugno (F)

Womens Cancer Research Center, Magee-Women's Research Institute and Hillman Cancer Center, Pittsburgh, PA, USA; Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA; Department of Epidemiology, University of Pittsburgh Graduate School of Public Health, USA.

Kirsten Moysich (K)

Division of Cancer Prevention and Control, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.

Roberta Ness (R)

School of Public Health, University of Texas Health Science Center at Houston (UTHealth), TX, USA.

Susan J Ramus (SJ)

School of Women's and Children's Health, Faculty of Medicine, University of NSW Sydney, Sydney, New South Wales, Australia; The Kinghorn Cancer Centre, Garvan Institute of Medical Research, Sydney, New South Wales, Australia.

Jean Richardson (J)

Adult Cancer Program, Lowy Cancer Research Centre, University of NSW Sydney. Sydney, New South Wales, Australia.

Harvey Risch (H)

Chronic Disease Epidemiology, Yale School of Public Health, New Haven, CT, USA.

Mary Anne Rossing (MA)

Program in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA; Department of Epidemiology, University of Washington, Seattle, WA, USA.

Britton Trabert (B)

Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.

Nicolas Wentzensen (N)

Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.

Argyrios Ziogas (A)

Department of Medicine, University of California Irvine, Irvine, CA, USA.

Kathryn L Terry (KL)

Department of Epidemiology, Harvard TH Chan School of Public Health, Boston, MA, USA; Obstetrics and Gynecology Epidemiology Center, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.

Anna H Wu (AH)

Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.

Gillian E Hanley (GE)

Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, Canada.

Paul Pharoah (P)

Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK; Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.

Penelope M Webb (PM)

University of Queensland, School of Public Health, Brisbane, Australia; Department of Population Health, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia; Gynaecological Cancers Group, QIMR Berghofer Medical Research Institute, 300 Herston Road, Brisbane, QLD 4006, Australia.

Malcolm C Pike (MC)

Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Celeste Leigh Pearce (CL)

Department of Epidemiology, University of Michigan School of Public Health, Ann Arbor, MI, USA. Electronic address: lpearce@umich.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Sujet âgé › Menopausal hormone therapy prior to the...
questionsmedicales.fr › Thérapeutique › Traitement médicamenteux › Hormonothérapie substitutive › Oestrogénothérapie substitutive › Menopausal hormone therapy prior to the...
questionsmedicales.fr › Thérapeutique › Traitement médicamenteux › Hormonothérapie substitutive › Menopausal hormone therapy prior to the...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Menopausal hormone therapy prior to the...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Adulte d'âge moyen › Menopausal hormone therapy prior to the...
questionsmedicales.fr › Diagnostic › Pronostic › Stadification tumorale › Menopausal hormone therapy prior to the...
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Processus néoplasiques › Maladie résiduelle › Menopausal hormone therapy prior to the...
questionsmedicales.fr › Maladies endocriniennes › Troubles gonadiques › Maladies ovariennes › Tumeurs de l'ovaire › Menopausal hormone therapy prior to the...
questionsmedicales.fr › Phénomènes physiologiques des appareils urinaire et reproducteur › Phénomènes physiologiques de la reproduction › Développement sexuel › Climatère › Ménopause › Post-ménopause › Menopausal hormone therapy prior to the...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Effets physiologiques des médicaments › Hormones, substituts d'hormones et antagonistes d'hormones › Hormones › Progestines › Menopausal hormone therapy prior to the...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Statistiques comme sujet › Analyse de survie › Survie sans progression › Menopausal hormone therapy prior to the...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Statistiques comme sujet › Analyse de survie › Modèles des risques proportionnels › Menopausal hormone therapy prior to the...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Collecte de données › Registre civil › Mortalité › Taux de survie › Menopausal hormone therapy prior to the...